Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
D A Herrington(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore), Edgar P. Heimer(Roche (Switzerland)), Michael R. Hollingdale(Biomedical Research Institute), A. Felix(Clinique de La Source), Manuel Cortesia(University of Maryland, Baltimore), Elizabeth Nardin(Health First), Victor Nussenzweig(New York University), David F. Clyde(University of Maryland, Baltimore), Genevieve A. Losonsky(University of Maryland, Baltimore), James R. Murphy(University of Liverpool), Jonathan R. Davis(University of Maryland, Baltimore), Ruth S. Nussenzweig(New York University), Shahida Baqar(Naval Medical Research Command), Dieter Gillessen(Roche (Switzerland))
Cited by 503
Related Papers
Genetic Epidemiology of COPD (COPDGene) Study Design
|COPD Journal of Chronic Obstructive Pulmonary Disease|2010|1.3k
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933